The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
6 pts

Opinion on  Matrixx Initiatives Inc. (MTXX)     Sector: Healthcare  >  Industry: Biotechnology & Drugs
Everyone hates being sick!

May 05, 2008 10:56 PM GMT
Return Risk
-9.89% MID
Analyst

I have used zicam, which is Matrix main product, for a few years now and know how it can work. I see that it has been catching on because many of my family members and co-workers now use it. I see people buy zicam in mass quantities and use it at any sort of hint of illness. I have seen the product go to an oral form and have seen that they have been producing more products, which I think is great. I see good growth potential for this company.

MTXX:  This call was made on 05/05/08 @ $13.52
Rating:   Positive   $13.52 (05/05/08)
Gain/Loss:   -69.67% in 577 days
Target:   in > one year
Allocation:   12.4% of portfolio


Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.44% 381
2 Gerald Greene 18.14 +71.24% 211
3 stockmarketfunding.com 17.66 +25.60% 55
4 akiralegrand 13.47 +14.32% 62
5 anup2104 12.13 +74.22% 40


POPULAR STOCKS
Symbol Company Name Sentiment
YHOO Yahoo! Inc
MO Altria Group Inc
INTC Intel Corp
MSFT Microsoft Corp
BIDU Baiducom Inc ADS
PFE Pfizer Inc

TODAY'S HEADLINES

TODAY'S TOP PICKS

 
Matrixx Initiatives Inc. (MTXX)
   SocialPicks Sentiment:   

   This Quarter's Sentiment:
All:
65.0%
Top:
100.0%




Latest Picks by Ryan Hoopes
Symbol SP Sentiment Rating Return Since
TTEK Positive +14.20% 05/08/08
AXAS Positive -57.07% 05/05/08
KND N/A Positive -45.87% 05/05/08
XPH N/A Positive +18.36% 05/05/08
STX Positive -16.45% 05/05/08

View All >
   
Ryan Hoopes previously rated MTXX
Positive +0.00% Bullish on MTXX ...
05/05/2008
0





IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch